Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
AssigneeUniversity of Zurich
InventorsSteffen Gay, Mary Connolly, Caroline Ospelt
Life of this patent
Estimating the term…
Abstract
A miR-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to miR-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a miRNA decoy or sponge.
Claims9
A method for treating rheumatoid arthritis in a patient in need thereof, comprising administering to the patient a miR-323-3p inhibitor comprising a hybridizing sequence of nucleotides at least 90% identical to reverse complementary sequence of SEQ ID 1 or SEQ ID 2;
- thereby treating the rheumatoid arthritis.
A method for treating rheumatoid arthritis in a patient in need thereof, comprising administering to the patient a virus particle comprising:
- a nucleotide sequence capable of forming a hybrid to SEQ ID 1 or SEQ ID 2, wherein the nucleotide sequence is the reverse complement of a nucleotide sequence that is 90% identical to SEQ ID 1 or SEQ ID 2, and wherein the nucleotide sequence hybridizes to miR-323-3p or its precursor, thereby inhibiting expression of miR-323-3p, and thereby treating the rheumatoid arthritis.
Dependencies are inferred from the claim text.